CSL Partners with VarmX to Develop New Treatment for FXa Inhibitor Bleeding

MT Newswires Live

Sep 16

CSL (ASX:CSL) has partnered with VarmX to develop VMX-C001, a recombinant factor X protein to restore blood clotting in patients on Factor Xa inhibitors facing severe bleeding or requiring urgent surgery, according to a Tuesday Australian bourse filing.

The FXa inhibitor is used by more than 20 million patients globally for chronic anticoagulation therapy, with around 3% experiencing severe bleeding or requiring urgent surgery, the filing said.

The company will finance VarmX's global phase 3 trial and provide support for late-stage development, manufacturing, and pre-launch activities, per the filing.

The company will make an upfront payment of $117 million to VarmX for an exclusive option to acquire the company following phase 3 results, with potential additional payments of up to $388 million plus commercial milestones.

The treatment is slated for a commercial launch in 2029, the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2567412560"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567412560\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567412560?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 07:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567412560","market":"nz","top_or_hot":-1,"title":"CSL Partners with VarmX to Develop New Treatment for FXa Inhibitor Bleeding","media":"MT Newswires Live","content":"<html><body><p> CSL (ASX:CSL) has partnered with VarmX to develop VMX-C001, a recombinant factor X protein to restore blood clotting in patients on Factor Xa inhibitors facing severe bleeding or requiring urgent surgery, according to a Tuesday Australian bourse filing.</p><p>The FXa inhibitor is used by more than 20 million patients globally for chronic anticoagulation therapy, with around 3% experiencing severe bleeding or requiring urgent surgery, the filing said.</p><p>The company will finance VarmX's global phase 3 trial and provide support for late-stage development, manufacturing, and pre-launch activities, per the filing.</p><p>The company will make an upfront payment of $117 million to VarmX for an exclusive option to acquire the company following phase 3 results, with potential additional payments of up to $388 million plus commercial milestones.</p><p>The treatment is slated for a commercial launch in 2029, the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Partners with VarmX to Develop New Treatment for FXa Inhibitor Bleeding</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Partners with VarmX to Develop New Treatment for FXa Inhibitor Bleeding\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-16 07:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CSL (ASX:CSL) has partnered with VarmX to develop VMX-C001, a recombinant factor X protein to restore blood clotting in patients on Factor Xa inhibitors facing severe bleeding or requiring urgent surgery, according to a Tuesday Australian bourse filing.</p><p>The FXa inhibitor is used by more than 20 million patients globally for chronic anticoagulation therapy, with around 3% experiencing severe bleeding or requiring urgent surgery, the filing said.</p><p>The company will finance VarmX's global phase 3 trial and provide support for late-stage development, manufacturing, and pre-launch activities, per the filing.</p><p>The company will make an upfront payment of $117 million to VarmX for an exclusive option to acquire the company following phase 3 results, with potential additional payments of up to $388 million plus commercial milestones.</p><p>The treatment is slated for a commercial launch in 2029, the filing added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0728928796.USD","symbol_name":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2567412560","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567412560","pubTimestamp":1757979393,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CSL  has partnered with VarmX to develop VMX-C001, a recombinant factor X protein to restore blood clotting in patients on Factor Xa inhibitors facing severe bleeding or requiring urgent surgery, according to a Tuesday Australian bourse filing.The FXa inhibitor is used by more than 20 million patients globally for chronic anticoagulation therapy, with around 3% experiencing severe bleeding or requiring urgent surgery, the filing said.The company will finance VarmX's global phase 3 trial and provide support for late-stage development, manufacturing, and pre-launch activities, per the filing.The company will make an upfront payment of $117 million to VarmX for an exclusive option to acquire the company following phase 3 results, with potential additional payments of up to $388 million plus commercial milestones.The treatment is slated for a commercial launch in 2029, the filing added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","BK4086":"建筑产品","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","CSL.AU":"CSL LIMITED","BK7067":"生物科技","BK7511":"ESG概念","BK7508":"医药生物股","CSL":"卡莱尔伙伴","BK7501":"新冠治疗股","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC"},"translate_title":"CSL与VarmX合作开发FXa抑制剂出血新疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1,"CSL.AU":1},"content_text":"CSL (ASX:CSL) has partnered with VarmX to develop VMX-C001, a recombinant factor X protein to restore blood clotting in patients on Factor Xa inhibitors facing severe bleeding or requiring urgent surgery, according to a Tuesday Australian bourse filing.The FXa inhibitor is used by more than 20 million patients globally for chronic anticoagulation therapy, with around 3% experiencing severe bleeding or requiring urgent surgery, the filing said.The company will finance VarmX's global phase 3 trial and provide support for late-stage development, manufacturing, and pre-launch activities, per the filing.The company will make an upfront payment of $117 million to VarmX for an exclusive option to acquire the company following phase 3 results, with potential additional payments of up to $388 million plus commercial milestones.The treatment is slated for a commercial launch in 2029, the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}